AstraZeneca Plc (NASDAQ:AZN) released results from the EMERALD-1 Phase 3 trial of Imfinzi plus TACE concurrently, followed by Imfinzi with or without bevacizumab until progression versus transarterial chemoembolization (TACE) alone in 616 patients with unresectable hepatocellular carcinoma (HCC) eligible for embolization.
The data showed that Imfinzi (durvalumab), combined with TACE and bevacizumab, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) compared to TACE.
These results will be presented ...